Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$17.24 - $30.41
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.45M
Market Cap
$13.02B
Enterprise Value$71.53B
Total Cash (Recent Filing)$21.10B
Total Debt (Recent Filing)kr1.03B
Price to Earnings (P/E)11.5
Beta0.59
Next Earnings
Aug 07, 2025EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.30
Shares Outstanding641,203,900
10 Day Avg. Volume1,105,361
30 Day Avg. Volume1,447,636
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.24
Price to Sales (P/S)0.00
P/FCF Ratio10.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.33Price Target Upside56.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Genmab News
PremiumCompany Announcements
Genmab Executes Share Buy-back Transactions in May 2025---
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionThe potential of the company’s late-stage pipeline, namely Epkinly and Rina-S, offers long-term upside to revenue growth.
Revenue GrowthTotal revenues reflect roughly 19% year-over-year growth, and recurring revenue streams reflect 33% year-over-year growth, with growth primarily driven by greater Darzalex and Kesimpta royalties, as well as strong Epkinly and Tivdak sales.
Bears Say
Competitive ChallengesData to date in NSCLC for acasunlimab has been lackluster in a highly competitive space.
Patent Cliff ConcernOutlook remains guarded due to the lack of meaningful near-term catalysts and increasing concern about how Genmab will overcome the Darzalex patent cliff by 2030.
---
Ownership Overview
―
Insiders
0.82% Mutual Funds
0.01% Other Institutional Investors
98.33% Public Companies and
Individual Investors
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $17.23 and its highest was $30.41 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $13.02B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Aug 07, 2025 which is in 86 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on May 08, 2025. The company reported $0.305 earnings per share for the quarter, beating the consensus estimate of $0.235 by $0.07.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.4.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 641,203,900 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.305 in its last earnings report, beating expectations of $0.235. Following the earnings report the stock price went down -5.728%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GMAB
---
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.33 (56.66% Upside)
$30.33 (56.66% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 307.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.65%
12-Months-Change
Fundamentals
Return on Equity
22.69%
Trailing 12-Months
Asset Growth
21.65%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
---
GMAB Company Deck
---
GMAB Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance in 2024 with significant revenue and profit growth, driven by the success of commercialized medicines like EPKINLY and TIVDAK. The company has a robust pipeline with strategic investments and provided optimistic guidance for 2025. However, there are minor concerns about EPKINLY's flat sales in Q4 and the company's dependency on key products amid competitive pressures.Read More>---
GMAB Stock 12 Month Forecast
Average Price Target
$30.33
▲(56.66% Upside)
Technical Analysis
---